Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.

PubWeight™: 1.56‹?› | Rank: Top 4%

🔗 View Article (PMID 15745728)

Published in Am J Med on March 01, 2005

Authors

Rochelle P Walensky1, Milton C Weinstein, April D Kimmel, George R Seage, Elena Losina, Paul E Sax, Hong Zhang, Heather E Smith, Kenneth A Freedberg, A David Paltiel

Author Affiliations

1: Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts 02114, USA. rwalensky@partners.org

Articles citing this

Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns. PLoS Med (2006) 4.86

The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71

Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28

Routine opt-out HIV testing in an urban community health center. AIDS Patient Care STDS (2009) 1.74

Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70

Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy (2007) 1.65

The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat (2011) 1.41

Community views about routine HIV testing and antiretroviral treatment in Botswana: signs of progress from a cross sectional study. BMC Int Health Hum Rights (2007) 1.08

HIV testing of at risk patients in a large integrated health care system. J Gen Intern Med (2007) 1.03

The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend (2012) 1.01

Optimal investment in HIV prevention programs: more is not always better. Health Care Manag Sci (2009) 0.96

Next steps for Ukraine abolition of HIV registries, implementation of routine human immunodeficiency virus testing and expansion of services. Addiction (2010) 0.93

Health service barriers to HIV testing and counseling among pregnant women attending Antenatal Clinic; a cross-sectional study. BMC Health Serv Res (2014) 0.91

Modelling the potential population impact and cost-effectiveness of self-testing for HIV: evaluation of data requirements. AIDS Behav (2014) 0.87

Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One (2011) 0.86

Implications and impact of the new US Centers for Disease Control and prevention HIV testing guidelines. Curr Infect Dis Rep (2008) 0.83

Late diagnosis of HIV infection at two academic medical centers: 1994-2004. AIDS Care (2008) 0.82

HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment. Med Decis Making (2015) 0.81

Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Med Decis Making (2012) 0.79

Swab2know: An HIV-Testing Strategy Using Oral Fluid Samples and Online Communication of Test Results for Men Who Have Sex With Men in Belgium. J Med Internet Res (2015) 0.78

Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. PLoS One (2011) 0.78

Routine HIV screening in North Carolina in the era of the Affordable Care Act: update on laws, reimbursement, and tests. South Med J (2013) 0.75

Increase in CD4 count among new enrollees in HIV care in the modern antiretroviral therapy era. J Acquir Immune Defic Syndr (2014) 0.75

Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One (2013) 0.75

Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. J Gen Intern Med (2011) 0.75

Articles by these authors

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49

The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45

Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19

The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19

The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08

Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08

The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73

Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62

Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53

Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14

Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78

The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75

Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43

Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42

Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38

When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21

Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20

Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20

Identification of an organelle receptor for myosin-Va. Nat Cell Biol (2002) 4.06

Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96

Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis (2011) 3.86

Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84

Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med (2008) 3.69

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57

Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54

CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39

Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med (2008) 3.36

Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33

Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25

Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24

Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11

Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10

The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med (2006) 3.09

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09

Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09

Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08

Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell (2006) 3.01

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01

Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98

Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96

Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96

Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr (2008) 2.93

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med (2004) 2.92

Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91

FARP2 triggers signals for Sema3A-mediated axonal repulsion. Nat Neurosci (2005) 2.87

Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83

Melamine related bilateral renal calculi in 50 children: single center experience in clinical diagnosis and treatment. J Urol (2010) 2.83

Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell (2013) 2.83

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78